The Claim

In high-risk diabetic patients without known significant atherosclerosis, the addition of evolocumab (140 mg every 2 weeks) to statin therapy significantly reduces the composite risk of coronary heart disease death, myocardial infarction, ischemic stroke, or ischemia-driven revascularization (4-P MACE) by 31% over a median follow-up of 4.8 years, with a 5-year event rate of 7.6% in the evolocumab group compared to 10.5% in the placebo group.

Source: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
80score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

For people with diabetes who are at high heart risk but don’t yet have major artery blockages, adding a drug called evolocumab to their usual cholesterol medicine cuts their chance of heart attack, stroke, or heart-related death by about a third over nearly 5 years.

See the scientific wording

In high-risk diabetic patients without known significant atherosclerosis, evolocumab (140 mg every 2 weeks) added to statin therapy reduces the composite risk of coronary heart disease death, myocardial infarction, ischemic stroke, or ischemia-driven revascularization (4-P MACE) by 31% over 4.8 years, with a 5-year event rate of 7.6% vs 10.5% in the placebo group.

Why this might work

A drug blocks a protein that normally destroys cholesterol-clearing receptors in the liver, allowing more receptors to stay on the liver surface and remove more cholesterol from the blood. With less cholesterol circulating, less of it builds up in artery walls, which prevents new blockages from forming and reduces the chance of clots that cause heart attacks, strokes, or the need for artery-opening procedures.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

    For people with diabetes who are at high risk for heart problems but don’t yet have clogged arteries, adding evolocumab to their cholesterol medicine lowered their chance of having a heart attack, stroke, or needing heart surgery by about one-third over nearly five years.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.